U.S. flag

An official website of the United States government

NM_000371.4(TTR):c.94C>G (p.Leu32Val) AND Cardiovascular phenotype

Germline classification:
Pathogenic (1 submission)
Last evaluated:
May 14, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002377579.1

Allele description [Variation Report for NM_000371.4(TTR):c.94C>G (p.Leu32Val)]

NM_000371.4(TTR):c.94C>G (p.Leu32Val)

Gene:
TTR:transthyretin [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
18q12.1
Genomic location:
Preferred name:
NM_000371.4(TTR):c.94C>G (p.Leu32Val)
HGVS:
  • NC_000018.10:g.31592920C>G
  • NG_009490.1:g.6154C>G
  • NM_000371.4:c.94C>GMANE SELECT
  • NP_000362.1:p.Leu32Val
  • LRG_416t1:c.94C>G
  • LRG_416:g.6154C>G
  • NC_000018.9:g.29172883C>G
  • NM_000371.3:c.94C>G
Protein change:
L32V
Links:
dbSNP: rs2144406525
NCBI 1000 Genomes Browser:
rs2144406525
Molecular consequence:
  • NM_000371.4:c.94C>G - missense variant - [Sequence Ontology: SO:0001583]
Observations:
1

Condition(s)

Name:
Cardiovascular phenotype
Identifiers:
MedGen: CN230736

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002688387Ambry Genetics
criteria provided, single submitter

(Ambry General Variant Classification Scheme_2022)
Pathogenic
(May 14, 2021)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot provided1not providedclinical testing

Citations

PubMed

A novel ATTR L32V mutation causes familial amyloid polyneuropathy in a Bolivian family.

Martínez-Ulloa PL, Vallejo M, Corral I, García-Barragán N, Alcazar A, Martínez-Alonso E, Martínez-Poles J, Pian H, Jiménez-Escrig A.

J Peripher Nerv Syst. 2017 Sep;22(3):208-212. doi: 10.1111/jns.12227. Epub 2017 Jul 27.

PubMed [citation]
PMID:
28646538

New sequence variants in patients affected by amyloidosis show transthyretin instability by isoelectric focusing.

Hinderhofer K, Obermaier C, Hegenbart U, Schönland S, Seidler M, Sommer-Ort I, Barth U.

Amyloid. 2019 Jun;26(2):85-93. doi: 10.1080/13506129.2019.1598358. Epub 2019 May 10.

PubMed [citation]
PMID:
31074293
See all PubMed Citations (3)

Details of each submission

From Ambry Genetics, SCV002688387.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testing PubMed (3)

Description

The p.L32V pathogenic mutation (also known as c.94C>G), located in coding exon 2 of the TTR gene, results from a C to G substitution at nucleotide position 94. The leucine at codon 32 is replaced by valine, an amino acid with highly similar properties. This variant (also referred to as p.L12V) has been detected in unrelated index cases with transthyretin amyloidosis with features including polyneuropathy and cardiomyopathy, and was reported to segregate with disease in a family (Martínez-Ulloa PL et al. J Peripher Nerv Syst, 2017 09;22:208-212; Hinderhofer K et al. Amyloid, 2019 Jun;26:85-93). Other variants affecting this codon (e.g., p.L32P and p.L32M) have also been reported in association with amyloidosis (Brett M et al. Brain. 1999 Feb;122 ( Pt 2):183-90; Choi K et al. J Clin Neurol. 2018 Oct;14(4):537-541). Based on internal structural analysis, the p.L32V variant is anticipated to result in a decrease in structural stability (Schormann N et al. Amyloid. 1998 Sep;5(3):175-87). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknown1not providednot provided1not providednot providednot provided

Last Updated: Apr 15, 2024